Effect evaluation and prognosis of Chinese medicine based on Novel Coronavirus Pneumonia (COVID-19)

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000029747

Enrollment

Unknown

Registered

2020-02-11

Start date

2020-02-11

Completion date

Unknown

Last updated

2020-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Experimental group:Traditional Chinese Medicine

control group:Basic treatment of modern medicine

Eligibility

Sex/Gender

All

Age

12 Years to 80 Years

Inclusion criteria

Inclusion criteria: Conforming to the diagnostic standard of COVID-19; Participants in the first and second trials need to meet the diagnostic criteria of traditional Chinese medicine for epidemic diseases; Participants in the third trial need to meet the diagnostic criteria of deficiency of qi in lung and spleen of epidemic diseases.

Exclusion criteria

Exclusion criteria: Patients over 80 years of age or less than 12 years of age (trial 3 and less than 18 years old); patients with contraindications to study drugs; cancer patients, life expectancy <6 months; participants in other clinical trials in the past three months; pregnant women, breastfeeding Women.

Design outcomes

Primary

Measure	Time frame
Chest CT;Routine blood test;liver and renal function;TCM syndrome;	—

Countries

China

Contacts

Public ContactNianzhi Zhang

The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine

13505615645@163.com+86 13505615645

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026